Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Common Equity (2023 - 2025)

Historic Common Equity for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $196.4 million.

  • Zenas BioPharma's Common Equity fell 4535.09% to $196.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.4 million, marking a year-over-year decrease of 4535.09%. This contributed to the annual value of $312.5 million for FY2024, which is 23842.66% up from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Common Equity is $196.4 million, which was down 4535.09% from $239.6 million recorded in Q2 2025.
  • Zenas BioPharma's Common Equity's 5-year high stood at $359.4 million during Q3 2024, with a 5-year trough of -$288.8 million in Q2 2024.
  • For the 3-year period, Zenas BioPharma's Common Equity averaged around $47.0 million, with its median value being $196.4 million (2025).
  • As far as peak fluctuations go, Zenas BioPharma's Common Equity surged by 27773.4% in 2024, and later tumbled by 4535.09% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Common Equity stood at -$225.7 million in 2023, then surged by 238.43% to $312.5 million in 2024, then plummeted by 37.13% to $196.4 million in 2025.
  • Its Common Equity was $196.4 million in Q3 2025, compared to $239.6 million in Q2 2025 and $284.3 million in Q1 2025.